GlobeNewswire Inc | Jun 2, 2021 10:31AM EDT

June 02, 2021

LEXINGTON, Mass. and AMSTERDAM, June 02, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced its participation in the following upcoming virtual investor and scientific conferences:

-- Jefferies Virtual Healthcare Conference, June 1 - 4, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 2.A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 8:30 to 8:55 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- European Hematology Association (EHA) Virtual 2021, June 7 - 13, 2021uniQure will present two encore presentations respectively highlighting 26-week clinical data from the pivotal Phase 3 HOPE-B trial of the gene therapy etranacogene dezaparvovec in patients with severe to moderately severe hemophilia B.An oral presentation entitled 26 Week Efficacy and Safety of Etranacogene Dezaparvovec (AAV5-Padua HFIX Variant; AMT-130) in Adults with Severe or Moderate-Severe Hemophilia B Treated in the Phase 3 HOPE-B Clinical Trial will be available on June 11, 2021 at 9:00 a.m. ET. A poster presentation entitled Clinical Outcomes in Patients With and Without Pre-existing Neutralizing Antibodies to the Vector: 6-Month Data from the Phase 3 HOPE-B Gene Therapy Trial of Etranacogene Dezaparvovec will be available on June 11, 2021 at 9:00 a.m. ET -- Goldman Sachs 42nd Annual Global Healthcare Conference, June 8 - 11, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Tuesday, June 8.Matt Kapusta will participate in a fireside chat the same day at 4:40 to 5:20 p.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- uniQures Virtual Research & Development Day, June 22, 2021uniQure will host a virtual Research & Development Day on June 22, 2021 at 8:30 to 11:30 a.m. ET to highlight new investments in its expanding gene therapy pipeline focusing on CNS and rare, liver-directed disorders, as well as new advancements in platform technology and manufacturing. Additional details can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website. -- Raymond James Virtual Human Health Innovation Conference, June 21 - 23, 2021Members of uniQures management team will participate in virtual one-on-one investor meetings throughout the day on Wednesday, June 23.Ricardo Dolmetsch, president of research and development, will participate in a panel entitled Therapeutic Targets for Huntingtons Disease: We (Still) Down with HTT?, from 9:20 to 10:10 a.m. ET. A fireside chat with Matt Kapusta, chief executive officer, will take place the same day from 9:10 to 9:35 a.m. ET. The live webcast of the fireside chat can be accessed through the link displayed in the Investors & Newsroom section of the uniQure website.

About uniQure uniQure is delivering on the promise of gene therapy single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary gene therapies to treat patients with hemophilia B, Huntington's disease, Fabry disease, spinocerebellar ataxia Type 3 and other diseases.www.uniQure.com

uniQure Contacts:

FOR INVESTORS: FOR MEDIA: Maria E. Cantor Chiara Russo Tom MaloneDirect: 339-970-7536 Direct: 617-306-9137 Direct: 339-970-7558m.cantor@uniQure.com c.russo@uniQure.com t.malone@uniQure.com